VIOLIN Logo
VO Banner
Search: for Help
Vaxjo Home
Introduction
Statistics
News and Updates
Vaxjo Query
Selected Adjuvants
adamantylamide dipeptide vaccine adjuvant
aluminum hydroxide vaccine adjuvant
alhydrogel vaccine adjuvant
Data Submission
Data Exchange
Data Download
Documentation
FAQs
Disclaimer
Contact Us
UMMS Logo

saponin and MPLA nanoparticles

Vaxjo ID 260       
Vaccine Adjuvant Name saponin and MPLA nanoparticles       
Adjuvant VO ID VO_0005747
Description SMNP is a nanoparticle adjuvant combining Quil-A saponin, monophosphoryl lipid A (MPLA), cholesterol, and phospholipids. It mimics ISCOMs and enhances both innate and adaptive immune responses.       
Stage of Development Research       
Host Species for Testing Mouse       
Second Host Species for Testing Macaque       
Structure ~40 nm nanocages Molar ratio (Quil-A:Cholesterol:DPPC:MPLA) = 10:10:2.5:1 Physically incorporates MPLA into the nanoparticle       
Appearance Likely milky white suspension (common for liposomal/ISCOM structures)       
Preparation Components mixed with detergent, dialyzed, filtered, and purified via FPLC Sterile formulation in PBS, injected subcutaneously       
Dosage Mice: 5 µg Quil-A per dose, corresponding to 0.5 µg MPLA NHPs: 375 µg SMNP per side (total 750 µg)       
Function Saponin-containing adjuvants exhibited distinctive mechanisms of action, altering lymph flow in a mast cell–dependent manner and promoting antigen entry into draining lymph nodes. SMNP Together, these findings shed new light on mechanisms by which saponin adjuvants act to promote the immune response and suggest that SMNP may be a promising adjuvant in the setting of HIV, SARS-CoV-2, and other pathogens.       
Safety Safe in mice and NHPs       
References
Silva et al., 2021: Silva M, Kato Y, Melo MB, Phung I, Freeman BL, Li Z, Roh K, Van Wijnbergen JW, Watkins H, Enemuo CA, Hartwell BL, Chang JYH, Xiao S, Rodrigues KA, Cirelli KM, Li N, Haupt S, Aung A, Cossette B, Abraham W, Kataria S, Bastidas R, Bhiman J, Linde C, Bloom NI, Groschel B, Georgeson E, Phelps N, Thomas A, Bals J, Carnathan DG, Lingwood D, Burton DR, Alter G, Padera TP, Belcher AM, Schief WR, Silvestri G, Ruprecht RM, Crotty S, Irvine DJ. A particulate saponin/TLR agonist vaccine adjuvant alters lymph flow and modulates adaptive immunity. Science immunology. 2021; 6(66); eabf1152. [PubMed: 34860581].